Rocket Lab’s Whiplash Summer: Iridium’s $8 Billion Promise Meets Neutron’s Waiting Game

Rocket Lab's stock rebounds 17% after KeyBanc upgrade, Iridium acquisition reshapes balance sheet, Neutron rocket delayed to 2026. Analysts bullish with $115 target.

Rocket Lab’s stock ended last week at $100.46, a sharp recovery from the lows of the month — yet still miles below the record $150.23 touched on May 27. That 27.5% year-to-date gain masks a wild swing: the shares slumped into the low $80s during June before clawing back nearly 17% over just five trading sessions. The rally itself outpaced the S&P 500’s 1.7% gain by a factor of ten.

The immediate catalyst was a KeyBanc upgrade that called the broader space-sector selloff “unfounded.” The bank now rates Rocket Lab Overweight with a $135 target, painting the company as the clearest No. 2 behind SpaceX. Two successful missions — a rapid-response launch for the US Space Force under the VICTUS-HAZE program and a deployment for customer Synspective — added fundamental heft to the narrative.

But the bounce was nearly derailed by a last-second abort. On June 30, Rocket Lab scrubbed the launch of “The Grain Goddess Provides” at the T-zero moment, delaying a Japanese radar satellite built for iQPS. That mission was the eighth of 15 contracted flights for iQPS’s planned 36-satellite Earth-observation constellation. The company has not disclosed the cause nor set a new date.

That hiccup, however, is just one side of a two-front story.

The Iridium Bet That Reshapes the Balance Sheet

The bigger tension surrounds Rocket Lab’s proposed $8 billion acquisition of Iridium Communications. Confirmed on June 29, the deal values Iridium at $54 per share in a mix of cash and stock. Bank of America responded by lifting its price target from $105 to $115 and reiterating a Buy rating.

The acquisition transforms Rocket Lab from a pure-play launch provider into a satellite-communications heavyweight, challenging SpaceX’s Starlink. Yet it also brings dilution for existing shareholders and a new debt burden. The transaction is not expected to close before mid-2027, pending Iridium shareholder and regulatory approvals.

Street consensus remains constructive: all 17 analysts tracked by the company rate the stock a Buy, with an average price target of $103. Looking at the past six months alone, the median target among 15 updated estimates stands at $115 — well above current levels.

Neutron: The Rocket That Cannot Be Rushed

While Wall Street debates the Iridium math, the company’s center of gravity has shifted to a test stand in Virginia. The Neutron rocket, originally slated for a 2024 debut, is now targeting the fourth quarter of 2026. CEO Peter Beck has made it plain: the only acceptable outcome for the first flight is a clean orbit. “We refuse to roll an incomplete product to the pad,” he has said, urging observers to judge progress by hardware milestones, not calendar dates.

Neutron’s development has already blown past its initial $250 million budget. By end-2025, spending is expected to hit $360 million, with personnel costs alone running $15 million per quarter. The team in Middle River, Maryland, is currently installing flight avionics and fluid systems, after which the vehicle moves to Wallops Island for integrated system tests. A first-stage tank ruptured during ground testing early in 2026, forcing a design revision — a reminder that new architectures rarely fly flawlessly on the first try.

The stakes are enormous. Rocket Lab’s backlog stood at $2.2 billion at the end of the first quarter, with launch services accounting for 41% of that figure. A successful Neutron debut would unlock the lucrative Lane-1 program from the US government, a five-year framework worth $5.6 billion. A failure, on the other hand, would slam a stock already trading at roughly 62 times expected annual revenue, with a market capitalisation of $56.7 billion.

What Investors Are Watching Now

For the near term, two variables will drive the stock: the rescheduled iQPS launch and the pace of Neutron’s ground-validation milestones. The company has already booked a record block-sale of multiple Neutron launches from an undisclosed customer, signalling commercial confidence. But until the rocket actually reaches orbit, that contract remains paper.

The Iridium deal adds a layer of medium-term uncertainty. Dilution and debt will be factored in by the market long before the closing date. Meantime, the share price hangs on the rhythm of test-stand successes. As Beck himself has warned, smooth testing phases can be deceiving — actual hardware problems may only appear under flight-like stress. For Rocket Lab, the gap between promise and proof has rarely been narrower.